-
IJNS: Family caregivers participate in the care plan for patients with dementia
Time of Update: 2021-11-02
Petra EM Tasseron-Dries, Hanneke JA Smaling, et al Family involvement in the Namaste care family program for dementia: A qualitative study on experiences of family, nursing home staff, and volunteers , International Journal of Nursing Studies, 2021,https:// doi.
-
Neurology: For Parkinson's patients, if they are accompanied by rapid eye movement sleep, deep brain stimulation does not affect their prognosis
Time of Update: 2021-11-02
Among 215 PD patients who were followed up for 12 months after STN-DBS, they compared the motor, cognitive, psychological and behavioral characteristics and life of patients with (preoperative RBD+) or without possible RBD (preoperative RBD-) before surgery Quality results .
-
Lancet Neurol: Poor tolerability, negative efficacy-bexarotene is not recommended for the treatment of relapsing-remitting multiple sclerosis (CCMR ONE)
Time of Update: 2021-11-02
Another positive regulator of the differentiation of oligodendrocyte precursor cells is the retinoic acid X receptor (RXR) bexarotene, a non-selective agonist of α, β and γ subtypes and has been approved for use Treatment of skin T cell lymphoma .
-
Lancet Sub-Journal: The impact of integrating multi-domain interventions into comprehensive primary care on quality of life
Time of Update: 2021-11-02
preventionRecently, experts from the Aging and Health Research Center of National Yangming Jiaotong University in Taiwan have conducted related research to determine whether the inclusion of multi-domain interventions in primary care can improve health outcomes and quality of life based on standard values .
-
JPD: machine learning to assist Parkinson's disease prediction
Time of Update: 2021-11-02
They use questionnaire surveys and simple non-invasive clinical tests to predict the future diagnosis of PD .
Machine learning can use questionnaires and simple non-invasive tests to identify people who may develop PD in the prodromal period.
3233/JPD-212876 Predicting Parkinson's Disease and Its Pathology via Simple Clinical Variables.
-
Alzheimer & Dementia: Targeting Aβ to treat Alzheimer's disease?
Time of Update: 2021-11-02
The results showed that Aβ accounted for 16% of the cross-sectional cognitive impairment variation, tau accounted for 46%-47%, brain atrophy accounted for 25%-29%, but 53%-58% of the total cognitive impairment variation was caused by AD risk factors Intermediary and direct effects explained .
-
These 7 misunderstandings of stroke have pitted many people. How many do you know?
Time of Update: 2021-11-02
In addition, China's largest stroke or disabling disease, stroke, blood vessels less than 20% of patients can obtain basic recovery .
If the young and middle-aged people do not pay attention to prevention , strokes can also occur .
-
Lancet Neurol: How effective and safe is gene replacement therapy for infant symptomatic spinal muscular atrophy type 1?
Time of Update: 2021-11-02
Infections Recently, researchers have used broader eligibility criteria than those used by STR1VE-US to evaluate the safety and effectiveness of onasemnogene abeparvovec gene replacement therapy in infants with type 1 spinal muscular atrophy .
-
Neurology: NIH research in the United States, as long as the scientific research circle survives, it may be possible to succeed
Time of Update: 2021-11-02
The significance of this research lies in the discovery that the continuity of the research is an important and adjustable variable during the doctor-scientist training period, which can increase their career success rate and promote greater retention of the labor force .
-
Lancet Neurol: Is the oral brain penetrating BTK inhibitor tolebrtinib safe and effective in the treatment of relapsing multiple sclerosis?
Time of Update: 2021-11-01
At the 12th week of treatment, the number of new gadolinium-enhanced lesions decreased in a dose-dependent manner (average [SD] lesions per patient: placebo, 1.
At the 12th week of treatment, the number of new gadolinium-enhanced lesions decreased in a dose-dependent manner (average [SD] lesions per patient: placebo, 1.
-
Neurology: Determining the speech subtypes of patients with DeNovo Parkinson's disease: response to long-term treatment with levodopa
Time of Update: 2021-11-01
Clinically, the prosody subtype is characterized by more women and younger age, while the pronunciation subtype is more common in men, older age, heavier axial gait symptoms, and poor cognitive ability .
-
Neurology: Zhejiang University: bilateral basal ganglia arteries are blocked, the earlier the treatment, the better the effect
Time of Update: 2021-11-01
In this way, Hongfei Sang and others of Zhejiang University used data from the BASILAR Endovascular Treatment Study for Acute Basilar Artery Occlusion (BASILAR) to evaluate how OPT affects the efficacy and safety of EVT in patients with acute BAO in current clinical practice .
-
JAHA: Ischemic stroke in patients with acute decompensated heart failure
Time of Update: 2021-11-01
High BNP/NT-proBNP levels in men, ACS, previous heart failure hospitalization and admission were independently associated with ischemic stroke .
High BNP/NT-proBNP levels in men, ACS, previous heart failure hospitalization and admission were independently associated with ischemic stroke .
-
Lancet: The incidence of atrial fibrillation is getting higher and higher, and early screening of the elderly has obvious benefits!
Time of Update: 2021-11-01
All 75-76 year-olds living in these two regions were randomly assigned (1:1) and invited to participate in atrial fibrillation screening or control group .
Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial.
-
Aging: Only a slight decrease in memory?
Time of Update: 2021-11-01
references:Increased plasma brain-derived neurotrophic factor (BDNF) as a potential biomarker for and compensatory mechanism in mild cognitive impairment: a case-control study.
203598Increased plasma brain-derived neurotrophic factor (BDNF) as a potential biomarker for and compensatory mechanism in mild cognitive impairment: a case-control study.
-
Stroke: The wind is rising for Grilo
Time of Update: 2021-11-01
In this trial, for patients with mild to moderate acute non-cardiac ischemic stroke, ticagrelor combined with aspirin antiplatelet therapy (vs aspirin alone) can relatively reduce stroke by 17% .
They conducted a network meta-analysis (NMA) of multiple treatment options for randomized controlled trials to compare ticagrelor in the prevention of stroke in high-risk populations.
-
JAMA Sub-Journal: Lumbar puncture is not required. Plasma GFAP may be more sensitive in diagnosing early Alzheimer's disease!
Time of Update: 2021-11-01
Glial fibrillary acidic protein (GFAP) is a biomarker of reactive astrocyte hyperplasia, its blood level is higher in preclinical AD patients, and it is a promising candidate biomarker in the early stages of the disease .
-
JACC: Considering both systolic and diastolic blood pressure, how should the control target be set?
Time of Update: 2021-11-01
This study attempted to simultaneously analyze the associated risks of systolic blood pressure (SBP) and diastolic blood pressure (DBP) measurements and major comprehensive outcomes such as all-cause death, myocardial infarction (MI), congestive heart failure (CHF), or stroke .
-
Brain: Sleeping for 10 hours a day or sluggish?
Time of Update: 2021-11-01
The results show that even after adjusting for age, CSF total tau/Aβ42 ratio, APOE ε4 carrier status, years of education, and gender, sleep time alone is enough to affect the changes in brain cognitive abilities—at 7-8 hours of sleep duration The risk of cognitive impairment is the lowest .
-
Progress in diagnosis and treatment strategies of status migraine!
Time of Update: 2021-11-01
1. Principles of treatment① If there is no special contraindication, fully supplement the fluid lost by the patient;②In principle, use sudden frustration therapy (using larger doses of drugs to quickly stop the persistence of migraine symptoms, and clinically adopt a multi-drug combination program), non-opioid drugs, and multi-drug combination to control seizures;③Establish a reasonable expectation of SM treatment in the acute phase .
